About US
Contact us
-
Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and moreWith a self-proclaimed “Super Plant” already on the way in South Korea, Samsung Biologics CEO John Rim said in January that the CDMO’s expansion push was just getting started. He wasn’t kidding. The2021/8/25
-
Novartis' Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeededNovartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb recently found success. Kymriahc2021/8/25
-
Manufacturing issues force delay for PolarityTE's skin repair hopefulManufacturing issues are common with regenerative medicines. And so it goes for PolarityTE's investigational new drug submission for SkinTE. On Tuesday the Salt Lake Salt Lake City biotechrevealedtha2021/8/23
-
Lonza invests yet again, this time with a fill-finish line at new manufacturing site in Guangzhou, ChinaJust months after opening a new plant in Guangzhou, China, Lonza is expanding its capacity. Monday, the Swiss CDMOrevealedthat it is adding a new fill-finish line at the biologics manufacturing facil2021/8/23
-
PHEXCOM Events &Advertisement Cooperation 20222021/8/20
-
Viatris in talks with West Virginia University on plan that could keep idled Morgantown factory afloatWhile Viatris didn't find a buyer in time to save the former Mylan plant it shuttered last month, the company says it's looking to secure "the next best possible future" for the West Virginia facilit2021/8/16
-
J&J, Amgen and Roche face growing biosimilar competition that is driving down prices: reportFive years since the U.S. saw itsfirstmimic of a biologic drug with Sandoz’s Zarxio, new evidence suggests some innovator biologics are starting to feel the heat from their complex copycats. Between2021/8/16
-
With FDA verging on its first COVID booster approval, Pfizer and Moderna will have to recalibrate revenues—againPfizer and Moderna are getting used to readjusting their projected COVID-19 vaccine sales. Now another recalibration may be in order. The FDA is set toauthorizea third dose of their COVID-19 shots fo2021/8/13
-
Evotec's new Washington site is ready to roll, and the U.S. has already called first dibs for COVID-19 antibody suppliesWith its inaugural commercial plant, Evotec says it’s ready to drum up customers at every link of the biologics chain. Its first order of business? Making investigational COVID-19 antibody drugs for2021/8/13
-
AstraZeneca, Daiichi Sankyo build Enhertu's blockbuster case with breast cancer win against Roche's KadcylaAstraZeneca and Daiichi Sankyo’s Enhertu is shouldering big expectations. With a new head-to-head trial win against Roche’s Kadcyla, the companies are showing their antibody-drug conjugate could inde2021/8/10